The new Wegovy trial in children is attracting attention after researchers reported that 40.4% of treated children aged 6 to under 12 moved below the obesity BMI threshold after 68 weeks. That headline is significant, but it needs careful context. The study involved children with obesity, most had severe obesity at baseline, all participants received lifestyle support, and the detailed scientific results have not yet been fully presented.
On September 7, 2026, Novo Nordisk announced topline results from the phase 3 STEP Young trial. The company reported that once-weekly semaglutide produced a greater reduction in BMI than placebo when both were combined with nutrition and physical-activity support.
This Wegovy trial in children may eventually influence pediatric obesity treatment, but it does not mean Wegovy is suddenly appropriate for every child who is above a certain weight. Current regulatory status, individual medical assessment and the limitations of the available data all matter.
The STEP Young results are important early findings. They are not a recommendation for parents to obtain semaglutide for a child on their own. Questions about a child’s weight, growth or obesity treatment should be discussed with an appropriately qualified pediatric healthcare professional.
What Did the Wegovy Trial in Children Actually Find?
The STEP Young study is a randomized, double-blind, placebo-controlled multinational phase 3 trial involving 165 children with obesity aged 6 to under 12 years.
According to Novo Nordisk, children were assigned to semaglutide or placebo and both groups also received lifestyle modification involving a reduced-calorie diet and increased physical activity.
The primary endpoint examined the percentage change in BMI from baseline to week 68. The study met that endpoint, with the semaglutide group showing a greater BMI reduction than the placebo group.
The result receiving the most attention was a secondary outcome: 40.4% of children treated with semaglutide were below the obesity BMI threshold at week 68, compared with 0% receiving placebo, according to the trial-product analysis that assumes participants adhered to treatment.
More than 85% of the children reportedly had class II or class III severe obesity at the beginning of the study. This makes an important difference when interpreting the findings: the trial was not designed for children seeking cosmetic weight loss or for children whose weight had not been medically assessed.
Readers can review the official STEP Young trial record on ClinicalTrials.gov.
1. The 40.4% Figure Is Important — But Easy to Misunderstand
The most striking number from the Wegovy trial in children is 40.4%. It does not mean 40.4% of children were permanently “cured” of obesity.
It means that, under the reported trial-product analysis, 40.4% of children receiving semaglutide had moved into a BMI category below the obesity threshold at week 68.
Children’s BMI is not interpreted exactly like adult BMI. Because children are still developing, BMI is assessed relative to age and sex using BMI-for-age growth charts.
The CDC explains that childhood obesity categories are based on sex-specific BMI-for-age percentiles. A child’s BMI therefore needs to be interpreted in a growth and developmental context rather than simply applying adult BMI cutoffs.
See the CDC explanation of child and teen BMI categories for more detail.
2. Semaglutide Was Not Tested Without Lifestyle Support
One detail could easily disappear from social-media headlines: both groups received lifestyle modification throughout the trial.
According to the company announcement, this included a reduced-calorie diet and increased physical activity. Therefore, the trial should not be described as medication versus healthy habits.
Instead, researchers compared semaglutide plus lifestyle modification with placebo plus lifestyle modification.
This matters for families because pediatric obesity management can involve several parts of health at once, including nutrition, physical activity, sleep, growth, emotional wellbeing and medical factors.
For adult readers interested in building realistic everyday habits, HealthFling’s 30-Day HealthFling Journey focuses on gradual, sustainable lifestyle changes rather than extreme plans.
3. The Results Are Topline Data, Not Yet the Full Scientific Picture
The current Wegovy trial in children headlines are based primarily on results announced by Novo Nordisk, the manufacturer of Wegovy.
This distinction is important for a health story.
The company says detailed STEP Young results are scheduled to be presented at The Obesity Society’s ObesityWeek 2026 meeting in Washington, D.C., from November 14 to 17.
A full scientific presentation can provide details that a company announcement cannot completely show, such as additional outcomes, treatment discontinuations, adverse-event patterns, subgroup findings and statistical analyses.
That does not make the topline results unimportant. It simply means our interpretation should remain appropriately cautious until more complete data are available.
Read the official Novo Nordisk STEP Young announcement.
4. Current Under-12 Approval Has Not Automatically Changed
A successful clinical trial and a regulatory approval are not the same thing.
In the United States, current FDA prescribing information includes Wegovy for chronic weight management in adults and pediatric patients aged 12 years and older with obesity. The current labeling does not establish this weight-management indication for children younger than 12.
UK prescribing information similarly describes weight-management use in adolescents aged 12 and older who meet specified criteria and states that the safety and efficacy of semaglutide in children below 12 have not been established.
The new Wegovy trial in children therefore should not be interpreted as an automatic change in current prescribing rules.
For regulatory context, see the current FDA Wegovy prescribing information and current UK Wegovy Summary of Product Characteristics.
5. Safety Still Needs Careful Long-Term Evaluation
Novo Nordisk reported that the overall safety and tolerability seen in STEP Young were consistent with previous pediatric and adult trials involving semaglutide and liraglutide.
The company also reported that no new safety concerns related to growth or pubertal development were identified in the topline analysis.
Those statements are reassuring, but they do not mean the treatment is risk-free.
The detailed results will be particularly important because these participants are young children and obesity treatment may involve long-term health decisions. Researchers and regulators will need to consider the complete balance between potential benefits, adverse effects, treatment burden and what happens over longer follow-up.
For that reason, the Wegovy trial in children should be discussed as promising evidence that still requires full scientific and regulatory evaluation.
6. Childhood Obesity Is Not the Same as Adult Weight Loss
Much of the weight-loss advice online is designed for adults. Applying those messages directly to children can be inappropriate.
Children need adequate nutrition for growth and development. Their body size and composition naturally change as they grow, and BMI is only one part of a broader health assessment.
A clinician may consider growth history, family history, blood pressure, metabolic health, sleep, medications, physical activity, psychological wellbeing and other factors when assessing a child.
This is why aggressive calorie restriction, adult fasting plans or adult weight-loss calculators should not be casually applied to young children.
HealthFling offers free health and weight-management tools for general wellness planning, but our adult-oriented calculators are not substitutes for pediatric medical assessment.
7. The Biggest Question Is What Happens Next
The most useful interpretation of the Wegovy trial in children is not “Wegovy is now the answer for childhood obesity.”
A better question is: Will the complete data show a benefit-risk profile strong enough to influence future treatment recommendations or regulatory decisions for younger children?
The detailed STEP Young presentation expected in November should provide more information. Regulatory agencies would then follow their own processes if an application to expand the indication is submitted.
Longer-term questions also remain important. These include how benefits persist over time, what happens when treatment is stopped, how treatment interacts with growth and development over longer periods, and how trial results translate into everyday clinical care.
Why the New Findings Matter for Parents
For families dealing with severe childhood obesity, the new trial may represent an important development because treatment options for younger children are limited.
At the same time, a headline number cannot tell an individual family whether medication is appropriate.
The trial population had medically defined obesity, and most participants began the study with severe obesity. The results should therefore not be generalized to every child with a larger body size or used to promote unnecessary weight loss in otherwise healthy children.
Parents concerned about a child’s growth or weight can start with a healthcare professional who can interpret growth charts and assess overall health in context.
What the STEP Young Result Does Not Prove
There are several conclusions we should not draw from the current announcement.
It does not prove that semaglutide permanently cures childhood obesity. It does not show that every child will respond similarly. It does not establish that treatment benefits outweigh risks for every patient. And it does not mean diet, activity or other aspects of health no longer matter.
The Wegovy trial in children also cannot yet answer every long-term question because the most detailed results are still awaiting scientific presentation.
This is exactly why responsible health coverage should explain both the promising result and the uncertainty that remains.
Frequently Asked Questions
What is the STEP Young trial?
STEP Young is a randomized, double-blind, placebo-controlled multinational phase 3 study evaluating semaglutide in children with obesity. The newly announced results focus on children aged 6 to under 12.
How many children were included in the trial?
The phase 3 study involved 165 children with obesity aged 6 to under 12 years.
What did the Wegovy trial in children report after 68 weeks?
Novo Nordisk reported that 40.4% of semaglutide-treated children were below the obesity BMI threshold at week 68 compared with 0% receiving placebo under the trial-product analysis. Both groups also received lifestyle modification.
Does 40.4% mean childhood obesity was cured?
No. Moving below an obesity BMI classification at one study timepoint is not equivalent to proving a permanent cure. Longer-term outcomes and what happens after treatment remain important questions.
Is Wegovy approved for weight management in children under 12?
Current US and UK prescribing information describes pediatric weight-management use from age 12 under specified criteria. The new trial announcement does not by itself change the approved age range.
Were diet and physical activity part of the study?
Yes. Both groups received lifestyle modification involving a reduced-calorie diet and increased physical activity.
When will more detailed STEP Young results be available?
Novo Nordisk says detailed results are planned for presentation at ObesityWeek 2026 in Washington, D.C., from November 14 to 17.
The Bottom Line
The new Wegovy trial in children produced a striking topline result: 40.4% of semaglutide-treated children aged 6 to under 12 moved below the obesity BMI threshold at week 68 compared with none receiving placebo, according to the reported trial-product analysis.
But several pieces of context matter just as much. Both groups received lifestyle support, most participants had severe obesity, current under-12 weight-management approval has not automatically changed, and detailed scientific results are still to come.
For parents, this is a development worth following — not a reason to self-treat a child.
HealthFling will update this article when more complete STEP Young findings become available.
Medical disclaimer: HealthFling provides general educational information and does not offer individual medical diagnosis or treatment advice. Parents and caregivers concerned about a child’s weight, growth or health should consult an appropriately qualified pediatric healthcare professional. Prescription medicines should only be used under appropriate medical supervision.